Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7427640 | 1.00 | KDM4E (0.47) | KDM4EKMT2ANFKB1ALDH1A1MEN1 | |
| SCHEMBL7424866 | 0.99 | KDM4E (0.47) | KDM4EKMT2ANFKB1ALDH1A1MEN1 | |
| SCHEMBL7424869 | 0.99 | KDM4E (0.47) | KDM4EKMT2ANFKB1ALDH1A1MEN1 | |
| SCHEMBL7478843 | 0.98 | KDM4E (0.45) | KDM4EKMT2ANFKB1ALDH1A1MEN1 | |
| SCHEMBL7478838 | 0.98 | KDM4E (0.45) | KDM4EKMT2ANFKB1ALDH1A1MEN1 | |
| SCHEMBL7427406 | 0.87 | FHIT (0.43) | KDM4EKMT2ANFKB1MEN1MAPT | |
| SCHEMBL7427401 | 0.87 | FHIT (0.43) | KDM4EKMT2ANFKB1MEN1MAPT | |
| SCHEMBL7422283 | 0.85 | KDM4E (0.48) | KDM4EKMT2ANFKB1ALDH1A1MEN1 | |
| SCHEMBL7428454 | 0.84 | KDM4E (0.47) | KDM4EKMT2ANFKB1ALDH1A1MEN1 | |
| SCHEMBL7481793 | 0.82 | ALDH1A1 (0.47) | KDM4EKMT2ANFKB1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6350885-B1 | TREATMENT OF MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, AORTIC ANEURYSM, HEART FAILURE, LEFT VENTRICULAR DILATION, RESTENOSIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, TREATMENT OF BURNS, DECUBITAL ULCERS, WOUND HEALING AGENT | WARNER-LAMBERT COMPANY | 2002-02-26 | — | — | US | claimed |
| WO-2000006560-A1 | TRICYCLIC HETEROAROMATICS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 2000-02-10 | — | — | WO | claimed |
| US-8847003-B2 | Role of proteoglycans in drug dependence | SANNA PIETRO P (US) | 2014-09-30 | — | — | US | disclosed |
| US-8847003-B2 | Role of proteoglycans in drug dependence | SANNA PIETRO P (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140173764-A9 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140173764-A9 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2014-06-19 | — | — | US | disclosed |
| US-20120174240-A1 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120174240-A1 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2012-07-05 | — | — | US | disclosed |
| US-8119854-B2 | Role of proteoglycans in drug dependence | Sanna, Pietro P. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119854-B2 | Role of proteoglycans in drug dependence | Sanna, Pietro P. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100199361-A1 | Role of Proteoglycans in Drug Dependence | Sanna, Pietro Paolo (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100199361-A1 | Role of Proteoglycans in Drug Dependence | Sanna, Pietro Paolo (US) | 2010-08-05 | — | — | US | disclosed |
| US-6350885-B1 | TREATMENT OF MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, AORTIC ANEURYSM, HEART FAILURE, LEFT VENTRICULAR DILATION, RESTENOSIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, TREATMENT OF BURNS, DECUBITAL ULCERS, WOUND HEALING AGENT | WARNER-LAMBERT COMPANY | 2002-02-26 | — | — | US | disclosed |
| WO-2000006560-A1 | TRICYCLIC HETEROAROMATICS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140173764-A9 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | OGFR, CSGALNACT1, OPRL1 | KDM4E 3408/4885KMT2A 3147/4885NFKB1 3274/4885 |
| US-20120174240-A1 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | OGFR, CSGALNACT1, OPRL1 | KDM4E 3408/4885KMT2A 3147/4885NFKB1 3274/4885 |
| US-20100199361-A1 | Role of Proteoglycans in Drug Dependence | OGFR, CSGALNACT1, OPRL1 | KDM4E 3408/4885KMT2A 3147/4885NFKB1 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.